0001328143-21-000043.txt : 20210510 0001328143-21-000043.hdr.sgml : 20210510 20210510160402 ACCESSION NUMBER: 0001328143-21-000043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210510 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210510 DATE AS OF CHANGE: 20210510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36399 FILM NUMBER: 21907029 BUSINESS ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-3554 MAIL ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 8-K 1 adms-20210510.htm 8-K adms-20210510

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 10, 2021
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer Identification No.)
1900 Powell Street, Suite 1000
Emeryville, CA 94608
(Address of principal executive office)
Registrant’s telephone number, including area code (510) 450-3500
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: 
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per shareADMSThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02    Results of Operations and Financial Condition.
On May 10, 2021, Adamas Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits
Exhibit No.    Description
99.1 Press Release dated May 10, 2021.
Cover Page Interactive Data File (embedded within the Inline XBRL document).


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Adamas Pharmaceuticals, Inc.
Dated: May 10, 2021By:/s/ Christopher B. Prentiss
  Christopher B. Prentiss
  Chief Financial Officer

EX-99.1 2 adms99103312021earningsrel.htm EX-99.1 Document
Exhibit 99.1

Adamas reports first quarter 2021 financial results
First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020
GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020

EMERYVILLE, Calif., May 10, 2021 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the first quarter ended March 31, 2021, and recent corporate highlights.
“Our commercial execution is effectively raising awareness of GOCOVRI and its expanded label, enabling more patients, caregivers and physicians to make GOCOVRI their treatment of choice in Parkinson’s related motor complications,” said Neil F. McFarlane, Chief Executive Officer. “We are also delighted to expand our commercial footprint beyond Parkinson’s disease, leveraging OSMOLEX ER to benefit patients with drug-induced extrapyramidal reactions. Despite continued market disruption, the growth of our products and our strong cash position gives us confidence in our ability to deliver long-term shareholder value.”
Recent portfolio highlights
Total revenues were $19.3 million in the first quarter of 2021, an increase of 33% as compared to $14.5 million in the first quarter of 2020.
GOCOVRI® (amantadine) extended release capsules product sales were $17.7 million in the first quarter of 2021, an increase of 22% as compared to $14.5 million in the first quarter of 2020.
Total paid prescriptions (TRx) of GOCOVRI were approximately 8,735 in the first quarter of 2021, a 21% increase over approximately 7,205 TRx in the first quarter of 2020.
Strong patient persistence of 45%-50% at 12 months continued in the first quarter of 2021.
New paid prescriptions (NRx) of GOCOVRI were approximately 590 in the first quarter of 2021, an 18% increase over NRx of approximately 500 in the first quarter of 2020.
In February 2021, the U.S. Food and Drug Administration approved a second indication for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinson’s disease patients experiencing OFF episodes.
Reached a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving patent litigation between the two parties relating to Zydus’ ANDA referencing GOCOVRI. Under the agreement Adamas granted Zydus a non-exclusive license to begin selling a generic version of GOCOVRI as of March 4, 2030, or earlier in certain circumstances.
Closed the settlement of patent litigation with Osmotica Pharmaceuticals plc. and acquisition of the global rights to OSMOLEX ER® (amantadine) extended release tablets in January 2021. OSMOLEX ER product sales were $0.3 million in the first quarter of 2021.
Corporate highlights
New data analyses published in peer-reviewed journal Frontiers in Neurology in March 2021 and presented at the American Academy of Neurology 73rd Annual Meeting, April 17-22, 2021

demonstrated GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease.
Presented data at AAN April 2021 highlighting that, despite the widespread prevalence and impact of OFF episodes and dyskinesia, there remains significant misunderstanding by people with Parkinson’s and their care partners of these motor complications and appropriate management strategies.
Adamas launched the national ‘Picture More Time℠’ disease education campaign to raise awareness and understanding of motor complications and their associated negative social and emotional impacts.
Patents issued (U.S. Patent: 10,973,783 and 10,987,324) in April 2021 covering ADS-4101, an investigational high-dose, modified release lacosamide capsule for partial onset seizures in patients with epilepsy. Efforts continue to partner or out-license this program.
Financial results
Total revenue was $19.3 million for the first quarter of 2021, consisting of GOCOVRI product sales of $17.7 million, OSMOLEX ER product sales of $0.3 million and royalty revenue earned on net sales of NAMZARIC® (memantine hydrochloride extended release and donepezil hydrochloride) capsules of $1.3 million. GOCOVRI product sales were up 22% compared to $14.5 million in the same period in 2020.
Research and Development (R&D) expenses
R&D expenses for the first quarter of 2021 were $1.8 million, compared to $2.5 million for the same period in the prior year. The decrease in R&D expenses was primarily due to the completion of the Company’s open-label extension trial for the treatment of multiple sclerosis patients with walking impairment.
Selling, General and Administrative (SG&A) expenses
SG&A expenses for the first quarter of 2021 were $26.6 million, compared to $24.6 million for the same period in the prior year. SG&A expenses in the first quarter of 2021 were primarily attributable to sales force costs and external spend dedicated to GOCOVRI commercialization and the related administrative support as well as the integration and initial promotion of OSMOLEX ER.
Net loss
Net loss was $12.6 million, or $0.36 per share, basic and diluted, for the first quarter of 2021, compared to a net loss of $16.6 million, or $0.59 per share, basic and diluted, for the first quarter of 2020. Net loss for the first quarters of 2021 and 2020 included $1.7 million and $1.5 million, respectively, in non-cash stock-based compensation expense.
Cash and investments
As of March 31, 2021, Adamas had $127.4 million of cash, cash equivalents and available-for-sale securities, compared to $83.4 million at December 31, 2020. During the first quarter of 2021, Adamas raised net proceeds of approximately $7.2 million under an at-the-market offering. In addition, in February 2021, Adamas sold 14,375,000 shares of its common stock through an underwritten public offering at a price of $4.40 per share, resulting in net proceeds to Adamas of approximately $59.3 million.

Full year 2021 expense guidance
For full year 2021, Adamas is reiterating its estimates for R&D, SG&A and stock-based compensation expenses as set forth below:
Full Year 2021
R&D expenses
$5 million -- $10 million1
SG&A expenses
$110 million -- $120 million2
Total operating expenses
$115 million -- $130 million3
1Includes stock-based compensation expense of $1 million.
2Includes stock-based compensation expense of $8 million.
3Includes stock-based compensation expense of $9 million.
Investor conference call and webcast
Adamas will host a conference call and webcast today, May 10, 2021, at 4:30 p.m. ET (1:30 p.m. PT). The conference call can be accessed by dialing 1-877-407-9716 for participants in the U.S. or Canada and 1-201-493-6779 for international callers. All callers must provide the following Conference ID: 13718098. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay for approximately 30 days.
GOCOVRI® (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes.
Taken once daily at bedtime, GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day. Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls and orthostatic hypotension.
For more information about GOCOVRI, please visit www.GOCOVRI.com.
OSMOLEX ER® (amantadine) extended release tablets is FDA-approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. OSMOLEX ER is contraindicated in patients with end-stage renal disease (i.e., creatinine clearance below 15 mL/min/1.73 m2). The most common adverse reactions reported in ≥ 5% of patients at the recommended dosage of immediate-release amantadine were nausea, dizziness/lightheadedness, and insomnia.
For more information about OSMOLEX ER, including the full Prescribing Information, please visit www.OSMOLEX.com.
For more information, please visit www.NAMZARIC.com.

About Adamas
At Adamas our vision is clear - to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.
Forward-looking statements
Statements contained in this press release regarding matters that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding Adamas’ expectations of its full year 2021 expenses. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas’ research, clinical, development and commercial activities relating to GOCOVRI, OSMOLEX ER, and ADS-5102, and the regulatory and competitive environment and Adamas’ business in general, see Adamas’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021, particularly under the caption “Risk Factors.” In addition, the impact that the current COVID-19 pandemic is having and will have on demand for GOCOVRI, and the unknown duration and severity of the COVID-19 pandemic, add additional risk and uncertainty to these forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.
# # #

Sarah Mathieson
Vice President, Corporate Communications
Peter Vozzo

— Financial Tables Attached —

Adamas Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except per share data)
 Three Months Ended
 March 31,
Product sales$17,978 $14,481 
Royalty revenue1,333 — 
Total revenues19,311 14,481 
Costs and operating expenses:  
Cost of product sales385 572 
Research and development1,812 2,465 
Selling, general and administrative, net26,639 24,552 
Total costs and operating expenses28,836 27,589 
Loss from operations(9,525)(13,108)
Interest and other income, net384 84 
Interest expense(3,432)(3,624)
Net loss $(12,573)$(16,648)
Net loss per share, basic and diluted$(0.36)$(0.59)
Weighted average shares used in computing net loss per share, basic and diluted35,167 28,030 

Adamas Pharmaceuticals, Inc.
Unaudited Consolidated Balance Sheet Data
(in thousands)
 March 31,
December 31,
Cash, cash equivalents, and available-for-sale securities$127,436 $83,365 
Total assets169,247 120,029 
Total current liabilities29,176 34,867 
Long-term debt126,159 126,307 
Total liabilities163,310 170,005 
Total stockholders’ equity (deficit)5,937 (49,976)

EX-101.SCH 3 adms-20210510.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 adms-20210510_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 adms-20210510_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 adms-20210510_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 adms-20210510_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 adms-20210510_htm.xml IDEA: XBRL DOCUMENT 0001328143 2021-05-10 2021-05-10 0001328143 false 8-K 2021-05-10 ADAMAS PHARMACEUTICALS, INC. DE 001-36399 42-1560076 1900 Powell Street Suite 1000 Emeryville CA 94608 510 450-3500 false false false false Common Stock, par value $0.001 per share ADMS NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.1
May 10, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 10, 2021
Entity Incorporation, State or Country Code DE
Entity File Number 001-36399
Entity Tax Identification Number 42-1560076
Entity Address, Address Line One 1900 Powell Street
Entity Address, Address Line Two Suite 1000
Entity Address, City or Town Emeryville
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code 510
Local Phone Number 450-3500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ADMS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001328143
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://adamaspharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports adms-20210510.htm adms-20210510.xsd adms-20210510_cal.xml adms-20210510_def.xml adms-20210510_lab.xml adms-20210510_pre.xml adms99103312021earningsrel.htm http://xbrl.sec.gov/dei/2019-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adms-20210510.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "adms-20210510_cal.xml" ] }, "definitionLink": { "local": [ "adms-20210510_def.xml" ] }, "inline": { "local": [ "adms-20210510.htm" ] }, "labelLink": { "local": [ "adms-20210510_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "adms-20210510_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "adms-20210510.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adms", "nsuri": "http://adamaspharma.com/20210510", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adms-20210510.htm", "contextRef": "i4c7bcba4f67c4781ba503b433fe75721_D20210510-20210510", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://adamaspharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "adms-20210510.htm", "contextRef": "i4c7bcba4f67c4781ba503b433fe75721_D20210510-20210510", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://adamaspharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001328143-21-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001328143-21-000043-xbrl.zip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

[&&V_F[U4"'E1 MI'SPB8R J @#]WP-*D"*,,ZE](+G5R^1CY26B$'@N@2(3Q1P7S#S0W%!?(2Y M5*7369S\>%G\$'RA'9-3N[N[%_:4U8HQ-RG0\D46 1?QR4;YX MD4J>EYP?Q.4T6A1_P=H,BI< 8?#0B_N%.GOSS'&6=&3I3'_1D5/\_O;E0V-( M-BDL)HF^*K[9SSJ+4_4UYUE^P86>&?2EM_SA1K\^6\3SFYE>OW:=Z:C>[2S+ M*EX+E*Q B?P"Y6]-P28]X!\);[Z+]0C@RG0_'@OC/DX_'@WNI:D/^O2 -\+T MAKP<4.\2-=38?0S5&_KI$1]K6*0YGPTP+)[";$">%2]64QD:F8[-SE4:"]FARW3RM.6W_V20!/VS$DSI3,S@ZU) MH3(&/V>Z\&4FN;J8QUX6\L\^19'.IMHGD5#(J!BC CQ P@#SL"+?(]X@1(! MYFWUW!QF;*(V2$%N0'666)T2;'MM[^'UL,"/P]:)5=Z-*"NQ'^:AA^+W.!], M]H<3W-1^"VO[ O NR>/\X8-9Y&8W:5;6$[/NR$VDVR3/'LY3I:=,,.E2-P#? MY:82"!H BS !%@8!8RX*L%!M*T&+>&,K"4O(3@7S:M4F8T+<[-Y:?L M,KU+IM)50:1]#$)X'A#,N9EB4 I:!X11IG& + O+3HR1%I,5SN=.@;08_ 56 MV^JQ2VC;BM&+IF&JA!U#']2\&NYX'EWYC:KN2;3>UE_C6=Q3+.X^3J M3U,ZLIC/IH&D0H540T0Y!N(B"LQ#&E#$*4->0'PP=EG,_3DZL9!LZK 3O/IU$2<:38DK"(E( M ()X$HC'(P@%ED:S6#,AD5 L[-25-Z.,3;K;76=UX11@G4^)]6V^7?W1?.-3 MC3SM(D^ 0-1T:\_T[5#X+K@D"C&A7&+:^I9?78"QB7Z-T5F#= J4%BV[CL06 M3;LG-:=NVW:LV'7N/:GWZ=UU;H?KWGN2JO3O?7;'Z^!XZE(B$=(^(.(Q(*&B M$/HA Y^[011$H#X[&)>6]?NKQ+^W=PW*.#6]'U*SOX/J:.TL'Q"3LX M_O4='-MT<-Q#_L62_6VF>7FKV*#$PFV9O95,ZU+MH=OYSHQCF8?$J7O_ZT?IMSWN.MS!=1CTE3RT%1R0GQ0$BFEHRCR.;6;NVU% M&%M)7\U&5BB=$J9C<-K.U[:);#M7ZT'/,/.T]LQTF)\U9-][;K;M=^!Y64-: MNW.R)L.NM4X3I+O+8R;R*XK=R/0-LPLK=GK(/\#[#1NPPT^1^X'!Q( M<[C MIBJBC%-&P.,1 U+^*,38ZKOK#&ZBS!.BNTMMVR MGMJVC;,W8U\;*(O03EIY"#\=_$/9PW7?@/" M(WN')=Z'DQ/KVI:.3CL/MO,^PJZ#1Y>#[SC83J9NM\&.C;U(WYJ>KXJ^_W[& MKZ:"4SPEUYQ,LKL\W6:K.]^**JI+/XA M1,( &_6Y/@@O]"!$D>=SCJB+<%OU;3L?FP!+?$X)T/JVT0YQAW78AXX32]&" M"2LY-J7<0Y$[+@<395,RF[ILM.FY_ZY\6NY3]CE+?\8&Z#0(-<*A0!!%"@%1 MB(#06H$*$0N1)R.F6I^&L2_0V"2[O;?L\>G.->".V_"V^6V[ENW/VC"+V0Z$ M==^-U\#&L3;D;;O_-7OR&I)LW);79-^S,'Q.%SF?_2>^*;>>(86TB!@"ZGO% MZE8I"'7 04B N9T"XH""P M"(!XV/]J53R/3>HK<,X277ME5^DZ+.;.))SZ'E:[_*WD6IMK#X56 M_0TFRMHT-G58;]#[4*L/B\6MSC:/8**ABB*J E"ZV"U/% .NF(#0Q4H*3[* MM)Z<'PHV-H'NG-NT1'R<&)Q]^*NS]%7C:0<[P"LW1"_ZABL MQF3W'(;5_)GNVT$>3S+]PRP,IF;!;JJ"ZP%FC)H%?1@""WP";N#Q &&N-6V] M7:LVPM@*Q>,>B25*Q\!T"ISV>T6J1!ZN"+WI.7$9L&:FTT:2VNR/L*.DZG?P MK26U:=7M,:DW[+H:_Z*OXN*)C20O'])FG(0XHAY(EX5F%HX0"$45>,)E@58N M4L+RC(MJ@+&)>;6L? )I^:1[+8EME]S=J1EFL=V6E0YK[/K4>Z^NM]P.O*ZN M3VIW1=U@UR3A3=XOS-6;9^M7XN69_F^>_1]02P,$% @ ?("J4LTAD;K9 M!@ AC, !4 !A9&US+3(P,C$P-3$P7W!R92YX;6S5FUMOVT83AN_]*U3U MMFOMD>0:L0O730KC9B4B%"DLZ=C^]]^0MM/XD):U6(B! 1VH M)6?VG4>SLR/ZU8_7ZW+V"6)3U-7AG.W3^0PJ5_NB6A[.?[]X0[+YCT=[>Z^^ M(^2/G]Z=S7ZNW>4:JG9V$L&TX&=71;N:??#0?)R%6*]G'^KXL?AD"#GJ3SJI M-S>Q6*[:&:>)3YJ4VQCF1_K \8 GSX)@F M*:62R$1Z8A*K\<$;*Q/&C?/]1@*0Z:_N!9[4S;:_Z/?LV^.J)[1^Z'D>X089P(MG_=^/G1WFQV M*T>L2W@'8=8]__[N]+-)X\W:-)N5B6NS[^KUHANP.*D1!W2U/[6]V<#AO"G6 MFQ+NCZTBA,.Y\>N&=#&EBM'.X/>W)R[^LKN)T" J_3S/\,#=^9V5?^\#7+=0 M>;B=U[V%LG8/!I6=JO7G,TMCH>R/YAZ*O+_JL6W::%R;FY J+VQ&E,T$D9HC M4I8[DIE$L(QJZESR<,J=RPWZW >A ;>_K#\M\,(8#*:[%Z1[02B["\'W3XS> MJO,R[^^_>1V'D&_V^"@N_,9 MSCI C.#/;F/SUNZ8AWN.SR$6M7]=^9]Q'T4GD2).L6Z+FSKV MRK_' ,!)?5FU\>:D]I!+!2+SWA'O,TN#,)% M3A>7L=6>!#QOBA)^NUQ;B#G3+&12)<2!RX@47A+#%(H3/%5>"9_Q,0JCQW8' M8:&FCL4+=9P$ Q?F^M2C5D4H;C8PB:NR?&(3)XES1F:9=8'2 M[#_$@P_"(_OV\/AWRDX)CQ-\^39>U%=5SIW($BH=235*(0/CQ(!/"0C!F>-4 M6.?&AN,O\X/0T-\(&B]4=4I@].7TVW@>ZT]%Y2 7-,42*BC"C3-$4IZ0+!,H M#@ANDN!2*T>GXY$/P[I?]!MA9!N!IP3*>=VTIORSV-QNNK217C+DVW!.I&>X M3*:&$L#-&)?&29S8V)@\\& 8)!/ND8XD[HX1Z3+@<033^ZT5GU9W6VS MFYP+<%PSABLIUFFV!A-K:>6A]$PX4;G MEF+N&(7S"!W'@&5O_VMP=U-!?!O0C]QEJ56.)218I[JF/4,MN"2F<]\IZS/- M1D#BZQX,0V/"7X3-XP;B^*MH0\S:A-'19*+ FRRXF<&)\J MC+'6E)J@E1EE@7ED=Q@4$^YS;B7DCB&XB*:[<_+]S=K69YDOEW B">#UM5N9:@G]?44\\XEAN,RE M7>Z25#NBG?.$)E8FP#PUH]R6\YSM8?=I3;ACN;6@D^A4OEY#7"+0O\3ZJEWA M+)^*=X8&CO;L/NH?N'S>.]OX/4$L#!!0 ( 'R JE(F MK7,4WQL + 861M9OEY\O;O_]Y1WIQ?V ?/G]'Q^N+LB1 M>7+RU;TX.;F\O23_O/WX@50MVR&W$0TEC[D(:7!R\N[3$3GJQ?'@].1D.!Q: M0]<24??D]OH$AZJ>!$)(9OFQ?_3V#7X#?S+JO_V?-W\S37(IO*3/PIAX$:,Q M\TDB>=@E7WTF[XAIID]=B,$HXMU>3"IVQ2%?173'[ZG^/>9QP-YFX[PYT9_? MG*A)WK2%/WK[QN?WA/N_'G';8:[=;+0;E/K51J-)*RW/;56K#GSON^W6?QU8 MY D\KM^1\2A@OQ[U>6CV&,Y_VJ@,XK,A]^/>J6/;/Q]-/1>S;[%) ]X-3]5J MX=>.@+VE/WLB$-'I*UO]=X:_F!W:Y\'H].^WO,\D^<2&Y%KT:?AW0P*$3)M7H M-Q:EBP6016^GWYJ'!XVZ )*VB&/1ATEA5EY%E5=N"CRO),NA@1RR$XVV]G%;GE( M0X_3 # ODR"62^E]FF;KSTJR3K9T-=(IC^%Q;PT0OI\D6"WJ8A&KS=VS, $) M(3KD)Z=EN036$8#\-0@EKOLSX2'*3\F(N(Q >H@11,:BT;(!$2I_DBH%@@(]<=Y\]$QKPS>GJ8KM8(']]=__N/ MJP\?WAD$!^Q8!OE(1UI,.@"[IQ<:LPM;(C1,\YFFW9#&GEA4K[?[5&E]Z=&H M3SV6Q-RC@30T6JY"SR+'GZCTZ5^_O*HUS\CYY<>;U\CQGN@/:#@B/O/A#;2: M8@$?[ED@!F@]T="'CP$'!L"/?7P,)ICMT>D9 E$<"BB^N#IR7RES3@89^.4IT+#W9FA3'IB CF M9 O4L?Z*A; %H,3(Z^DO7$?3HJ'V$#%/F88B@AE@GZ0'P L0@-+:@/W2;V(Q MF+-5GIL=%^/]EU?-2L4^^YQ$B,H^BQ30V#?F)2C2")>$*>@#!@, ,.7***9# M"DAB4HF\3"@BG#B FGT#DD!H!K3- H.PD+8#A7T1,1";,0=0 LX\&*.+E"'5 MJX/>2 )QP&80]8HTLI$!<1S0AW:YLM!A4J\G.! )#\D7"B9X*$6(>W$:9VAZ M!8H4^R(6:E^# (D31;2A-NR<$8G2^Q/C 7EOD8_>>QH%-&0@DWJ<=<@[#8![ M1CYW.C!/9)$44E^!'&$7P!Q"$3: 4A.]WC41TY#L"!$/@/1CTF8C ;_/KS8E M8H,$P#81[2*D/M]\_/SAW?^1=]=IFP<\'FEY MH 0 "6 $SBN3R3(&=83@0_?WM,@85:*E^UYZ87UV+46""AO.@+LGPF!L,$> M!M3W =]FP#KQJ;M80>NO -$PWZGI-)]CJTM5U.+-*V35SUY>44T#S*E8-1?! M<3MMF@Y!@TP;ITB42./3-AB0>B;A)VRUCC)CJ=2Z+=+<_9-3M6KKC&9OH@X* MC_X52J- Z$_5!.CM1O6,'(,E$\84GF.O42YJS0XZ0:'7HP,P"(!(4@$'BB 8 MDTS#:FQ',I7*@63*1#):8BQPX8YOK[^]GK1J%&70 9#+-]X'LP*LH*;1<&L/ MT0>I.+,>X/0H#:-BUPA,MYHVR($X7IHX;K2IDYI;X(5$DLM8&3> E6KM9[-F M [O'Q*F C1G&/3EA7:TBBP.COS@NET1JCC\]S.:UEOVP$IB/\\#(^,3,6/;* ML4JI DI%!U<_:$4!]E"(/YKZA".W3UP+0$2('^4:_C^/6$#+H7/-@H]'*AF"ZJY!C^ZER(_C@.F MT$F[$=/_4G[X?T8^.,!?113X0W"!R>7'BPM%3OJ'F9 :.?[]YOPUT2&U-*:@ M'DP=X-<8L1+!/=<*"&"C@B0AH)(UXX"M :OEH0$SD M_-/E.?RJ8VKX0$JN%OD]1.<;!QKO)XT"=B,PH%FV 4I"$9KLFQ/::08&-[.X=AG47!V@N%L2I2\A(I6(;M#1]&E.@>!J,)(88DG; 94\[ M!0/&(C-B]YP-X8L_11+!8\^5Z]DTVQNA^X*!>%CHIS3#,MI)%@X6H)6$RCFK MO H1*;T$7A]1G_1&R;+YHTG"?=-T-RZFM11-I2/Q4J^)[ M=H;2P'2M)KX."E')Q)2%VB#!<(2CMY&_$RB?AR R _*1,;0:#'(^B'A G(99 MJ>BLUW+I-UE]-+_I9?5(J7"QQZ_0-I@Y23S_R@/%/_K/7I2-/*!=9K;!UKXS M:0<$^"D-AG0DCS8JF]JVX&A=8?G"HA&X IQ<=&& :_(D6NZ/J#QR)!G%(E5._!*L*0EDK;]@?44S;>I'NIL_04D,),5E@@X%6NVX NRM]J81(\<]HS6#5B(P/Z*J#6Y=WDY7892T6'J)@8T"95WC+05 M4EV$J_+D3OWL"_?B!/#Z$64-UI3"]]6F?98YIEF0@X&%KGT)CP(1 MC1&< Z M S9198!XGZ8O()-E!**IBDHI/*XD8,BZ2CL1]4V@'F+HLZ@%:]H_4,VS2R_E M/8*)*27&R8]5[$U_J8N*'-MH-5RCT705AO!CLV&XE>IK5$(38LX3:3G1^>6- M677L+!UWSV3FF0)>41B:OL#*BK[P05!->(\!]83$6HD\(:AB>2J< J\")3$ M%N/?@83EO H$ 1FP@1Q9Y%VG@U6^>?Q?52UI48;1#="E9AXOZ7&5=>Q&M/^( MFJ$7]B3?9Y54.[%3GW?2Q3O>O'QW%^[_AA[>M:Z-*&:EZ.(E3Q5UD"$HG.F2 MCK2B;UEN!C@2LW:IKLB,X.F0D*IAGLCY&\NC1_CH9.Q(%06*$0WB4;Y&1J,0 MA S\&K*)]SZ=?_S/^?7511;7ZC,,;,%^26_D1\+K 1Q1$LW%N)3Y)4(V8-]! M]$T]_'I8]N5"QBTTS5*5@"+ _,,Z@ M$C^Z8%79D7KU7:!03WEH7\NV&:=/'YVE=S25;V8C7''#!%&Y4) MTLA&FJ$-_ I4,_PX H!:Y!8^^RQ-B,+O)KG8FC*$N.30:) M+W1U<>XS"!C"5%6EFEE4DB&.=*&E7MU4D6@?!#E''T1Z 8N$1 4\I?EI.]L]9L1>*5N MU9=1>'7\T[HD/K^(59D$O88QQ=,8*+:=J 0&+D&+9YC:0Q:0:*$$N8 MPI^NK\\$_+C.F']/L]7:__XF#3?U*&*ZTK"J.?+Q' CLV]"G$MA?"5=! MS52$TGO* Y2R)I"8B6(62WB2B&/)Q(P::+H3P](8+$*/]=M K^DR@& ODTB' M59>R47;R%X-7OF(CD* >8[Z<+PC[J6%5\@E5:$N5#\4FC&^F)S0$GH6".2UR MA95%/M>'-?A<*5,ZL12!3YRJX39J!F!)\Z::FZL01;\/C) MAP 5,*ATRM++9T904-1=NO3QIZI5M2?97OO*RH(*IS<,0$U7-;_UVH0;MYSG M#HFF GA5JV-#"=@0:!)I29U*4=)-N(^U.V42/^]!"76FMI-S%/,YW(0T-$I#]76U4NS26F@JY1<:TVKU:@BQ<9 IK&? M#9\2LZ6(^23VYW^K@G%26_ZS;3E;_M9LUK=Z<]5B:U7+KE?7&O9$ 4(# X J MP2O]]<@]&HL&%? ^M8FCD)*-]S2/5@;?\.'Y,^!S906*,IZ,D<%N":G874;%)\J,7<>_>"JX/W,Q MZ$[ZWESIL)I\T&'1B<:'_?:R0K]2?.@W]Q?Z3UNU_2S0;VT!_:F@3>W%JW>N M5#!85/2@S0CU/":E[DKE8PX.3!'';#8: M9M5NF*V&4Q_7E'DZVLVLV(Y9;;EFO=%HJ3:HB MV5J<8!-8J7:M3MRJ/WAD4;7L@3JG9@&CJ^^Q>B>69GK.1!>2OOQN=M3X3;$+ MLA.20)8P4>07,0P9JG].Q^^!08"M'M/W[(6EX'D;SS2D6?,RB;NM&MMP.9&C M4MV[0D#:^\MS,S_+GK7AR\ZR8\>\1?4S6QT#4;WRN#K G)UZ3S4K'A^@ Q#( M:@"8,#MN A(6F)''>)( G^_#I( ,3R\T[=RF\3$FRP-1;4A=.ZTK/@*J6S92(D&-D(CK&JXQX2E4 2#3 M:A%_G!,-(3 M5)[.YZM:,=BT:@&IJK^D[N8P01:)MMFRO?K<)Z&(875_)3P"J CDF!X-NTRE M*J>(3I,I'B11>K*/=H9.G@(D11MPHOI!^'C*G8U;[6G2FNHGTH,U)T!*&07[ M_/MWY"?\9S2"D9.X9ZA"HT%/%6PQG_6IKEV-^8#J?&\'1DG[\$4Q6CWPO4=Z MHX%(2^!*19N8:5,'T'@(,J>?5AU-2FB B!9I]WAFO&"&!;:5SWHH %'L0F67 M3?&.*\?*1*?;]B.0TZIVH5Y=KG]4!=4ZC3V5>/5!U.:J;:KU =='4B(ZUO#S MIUA"WP1ATD49%HZ[Z9)C;C'+T-<@@)1%H0][C#"EK]/4!,.*'Y22!:&I_G:L MADN>EAOV,=SS>DZE+- C>1=CP!@02-.NG9':SVD##HV_]"0\6%I8 JH($50: MHA*+??IH-@'.S?P@P5A_*[T44M"/=$(?*1RJDZ-X5P7SM8[2Y612]$-.]T7' MC'G$2"L*\Z(N3&1_T5W"VOCEU?CEPJND=%L'E?202LH.XY2=G M/D1F@BT>2 MA\+"0G&D-A)U0+%,7'F>]TO#=N?(AKI?OC*6B#G9^)R'H;C71S!F;D"(\/R[ M#MVVD\AG*L"Z\(X#/%:XM'<^'FQG,3C+67MZIME$LH92:#0@72U(5C54!Q4,: M^68@A(K/8"B"E>ZHP4V^:N4C@8N4M>U5!_21VC/#&9@,]JONKJ"Q.I:2WELR M(L+SDB@_^)6H9A?(>FE/Q\Y24&4W4* /EKZ>7H"2)5>^1/P>NYO+W)21$L,FG_"2.HYAYC_I$AFX5&"<3U[8@I/6= M,(@!AL$^$&MI"%'H@&VD\U:8,<-6(#HC)W$-RY&@Q17%]CA94V#RV'=V:-/0G M;Q]!C_*>SW4(S>-LD\Z0.BMZ>6/6'+MB3!PD[";PHHA&V=@#%G.ER5AXSR,1 MYO-.K[2-MRN_HX*A B8S./_4N?H0&<7BNO%]72>R1OQS;_13HG8.%C>!$2=[XU*,:\2G+7@/PR7N MF8AD=A_)],D;E1'5K9(41:A!DBA"$ !(KRY-IT74Y3=][J$MT*/W681;YZPI M [CYM@"P)_L'SP&>1+>A6*H8NOC(YD2[X;!ZU2RD]&SLQFXS'RIJK,F[&:: MDD?I26O)5G)&5C2@&1?H'4=D.H".[4T"ZN$J\>0V4!57<2$1/CBP088]CH)A M ):N3DK1K-T3-K1B^M\\%T969E\IC,7T#O >@H72#C)1"*M)!NI5;=DLF7JQ MK#. 03TV4*=AT[R DAP!'6X9['BN2^I6:K-7!/Z?6^]+MQI"?ENRB$VNJ&N] MN$ES@0K1BQ>?O'F>XS7@M%FV=MPV/5]3LZU6TWWRDS#5NM5T&D]Y$J88]<.+ M3ZQ\Q.CH-,(WK!A^)B \(=^N>1" 1K0'"A.$(Y/CFN GER+KK>8//&6* 5B\ M2"PVR+B),2KX),PJ 7:\3#"0S&K--MU:I;G^4C;T;==9RBK?5O8SI/[RJEX] M6^;F3I14;T[^,_&T]#SBLQR0VP.IDUM5!9(\H)-V(7:^,#PV_X?X_EWLF)>_ M DJ&W+MC*@%V=3&?H7[9]52KKEEQ7-.NV;7"RI8!HL^Z1_0IX3+,@/A$DF7- M6YK6K5@>]]M]WZ;_5HY\F272/]P7N9ER)[URO_/:2) MKT*0X&+Y&!E4_U)GG%5"8B(,B^VE]'&^1>9=479TK,(((H$Q?)E'#_)N**HI M]^O5JT_; 5<:.^@&O-!%WTS<%JWNKW=FP\N M=NV(P (]G&$K%*C;B_!DD8W]UEIFW RSS6Z_5906'[.[6>RYW/8BAHWZZD0#OT4PAZ'F,@<.ZVY#-@[D!>Z)I^MH1FZ6;?3(Z?PB:CQGC MJ1:Y!S3:4?\5C$:7Q-(FF[S/TN@F&[1)D;?YTZ.V-KDE=>-D(?;D-(Q6H[G8 M*MB0-,F&V]Q(/LQ,.2L"#D16:"*K&M6F4S0BVP,=44@[9DD3P^E[2I9:,I7- MMKN0F0M$^8;KNAL2_F*D/JMT7=>"VR_DI*F*HJ%G#^32"MGM5*Q*K: R:NJV MI^6M_%9Q0;KSM8,!!6<1IV6XSI::>Y. R"YMQQ\2KX^PR':$UST0BX4TUQ:' MG2[R2X#F>YP^.A2U @#%89'U(^7/&1#;+U#M 0^7*"R'/*PZ-JP*SVVB_4JD MX-QFK6CQAFRIE[*G2A+"]E9$;QYC9>U+^+/2-)IN?3LU7YBP]A,::'N#UX91:VZJ MJW:+UST0E26R[3ZHR[ZQ/8Z8/^OS ^>#CEM&K5)[79)4T"'%MPY*'==P[&99 M<+H'=98V+Z)-N@NVZ7NVK -YP MUP45O[;EUA^3*%BUYX)W!CC0:RGIM=8J![V63J,5;\%E>7*?PPE?U0>\<1Q6 M@U>\*G-!DB2]60COY$E4F5FXC5&Q218K9>.T2^@L)S]&G!='P+DUPZDW'A6[ M>1Q\2I35_!'HH=(T;-?>&WHHJ.Q>VO-]6=/GU=W;R];IO''T]M#I?"\ZG8_[ MF_^#!NIJM)L> [U\26-:V!U,=39_H(7Y#I>Y:0]S6-YS="QOM2S;;2*#;=RP MO&)5[.4_;]T#W+&:U>I6PS[4L+SU/(LM_UUC3]SRN11-BL?-OD&=K-GB>8N; MGPH-@TOFL7X;_*LQ&*8;-^^S*WI!)5X]"W\2O##SG@;Z8D]U2O.>\@ %I]D1 MD8G]+HC,[VL]),%_C&2B4VD8U7T_W74@WOTDWJ9KN-LV('AVVMWG9*@^.$NE M9/&/TB/)J;>,2G73,..AYOC%])AMV)4==E[89RLR/2>?1!'>S1YPVN;!0BMQ MDU!TB8BKTC*^3WS6_E&:^#B5 MNN'4#EU\"HP>U]ZA);;_JO['4_%.'7Q)9\NL\4''/SMZ&F#>VSOL-;C/2E[S MO(R%=]<3@<\BJ2[[:)RIF'$\(L<^ZW"/QW-5A'NJ86I&RSUX^@5%SG&U9;0: MFU=@/YD4F*M\*4]]RTE;^"/XJQ?W@[?_#U!+ 0(4 Q0 ( 'R JE)\ 5&4 MG10 )V- 1 " 0 !A9&US+3(P,C$P-3$P+FAT;5!+ M 0(4 Q0 ( 'R JE+5FUM:B ( '<) 1 " &UL4$L! A0#% @ ?("J4H2^$IJ<"@ H6$ !4 M ( !